We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NICE Issues Guidance on Tests for Cancers, Bacterial Infection

NICE Issues Guidance on Tests for Cancers, Bacterial Infection

June 5, 2015

The UK’s health care costs regulator is recommending against coverage of two new tests to help diagnose prostate cancer in people who have had a negative or inconclusive prostate biopsy, saying they aren’t an efficient use of government funds.

In final guidance issued last week, the National Institute for Health and Care Excellence said that using Hologic GenProbe’s Progensa PCA3 and Beckman Coulter’s Prostate Health Index to help determine the need for a second biopsy doesn’t lead to improvements in the diagnosis of prostate cancer that are large enough or consistent enough to influence current clinical diagnostic practice.

NICE also recommended against Caliber I.D.’s VivaScope 1500 and 3000 systems for diagnosing potentially malignant skin lesions, saying in draft guidance that while they show promise, there is insufficient evidence to recommend their use in routine clinical practice.

In another draft guidance released last week, NICE recommended five procalcitonin assays — Siemens Healthcare Diagnostics’ Advia Centaur, Thermo Fisher Scientific’s Sensitive Kryptor, DiaSorin’s Liaison BRAHMS PCT, bioMerieux’s Vidas BRAHMS PCT and Roche Diagnostics’ Elecsys BRAHMS PCT — for research use only, pending the outcome of further studies on their effectiveness in clinical practice. The assays measure levels of the biomarker procalcitonin to show whether infections have been caused by bacteria.

Final guidance on the procalcitonin tests and the VivaScope 1500 and 3000 imaging systems is expected in October and November, respectively.

The final guidance on Progensa PCA3 and PHI is available at www.fdanews.com/06-15-NICE-Guidance.pdf.

Comments on the two draft guidances are due June 24. View the drafts at www.fdanews.com/06-15-NICE-Guidance2.pdf and www.fdanews.com/06-15-NICE-Guidance3.pdf. — Jonathon Shacat

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Vaccine needle

    Turkish Researchers Downgrade Sinovac’s COVID-19 Vaccine Efficacy Rate

  • Luminex logo

    Luminex Receives EUA for Expanded Respiratory Pathogen Panel, Clearing It for COVID-19

  • Acquires -Acquired

    Amgen to Buy Five Prime Therapeutics for $1.9 Billion

  • abbott-logo.gif

    Abbott Secures EUA for COVID-19 Combination Test

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing